Posted March 23, 2017
Genome Medical, Inc., a rapidly growing genomics precision medicine company integrating genomic medicine into everyday health care, announced its inaugural Scientific Advisory Board membership.
"Our scientific advisors are visionary leaders and innovators who bring an unparalleled depth of expertise to Genome Medical," said company co-founder Robert C. Green, MD, MPH, chair of the scientific advisory board and director of the Genomes2People research program at Brigham and Women's Hospital, Broad Institute, and Harvard Medical School. "Their input will be invaluable as we bring greater access to genomic medicine to both patients and providers this year."
Genome Medical's mission is to help patients and healthcare providers use genetic services to improve health, lower the cost of care, and prevent disease.
In addition to Dr. Green, the advisory board members include:
- Euan Ashley, FRCP, DPhil, associate professor of Medicine, Genetics and Biomedical Data Science at Stanford and director of the Center for Inherited Cardiovascular Disease, co-director of the Clinical Genomics service, and co-director of the Stanford Data Science Initiative. In 2010, he led the team that carried out the first clinical interpretation of a human genome.
- Gerard T. Berry, MD, director of the Metabolism Program at Children's Hospital Boston, professor of Pediatrics at Harvard Medical School, director of Harvard's Biochemical Genetics Training Program, and associate member at the Broad Institute of MIT and Harvard. A leader in metabolic genetics, he is 2019 president-elect of the Society of Inherited Metabolic Disorders.
- Heather Hampel, MS, CGC, associate director of the Division of Human Genetics and associate director of biospecimen research at The Ohio State University Comprehensive Cancer Center and former president of the American Board of Genetic Counseling. Ms. Hampel is an internationally recognized cancer genetic counselor whose research has led to changes in standard-of-care genetic screening practices for colon cancer.
- Bruce R. Korf, MD, PhD, chair of the Department of Genetics and Director of the Heflin Center for Genomic Sciences at the University of Alabama at Birmingham. He is current president of the American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine and has held leadership roles in most of the major genetics professional societies. In addition, Dr. Korf is at the forefront of developing novel approaches for integrating genetics and genomics into medical practice.
- Robert L. Nussbaum, MD, chief medical officer of Invitae. He is the former chief of the University of California, San Francisco's Division of Genomic Medicine and medical director of the Cancer Risk Program and the UCSF Program in Cardiovascular Genetics. He is also the former chief of the Genetic Diseases Research and Inherited Disease Research Branches of the National Human Genome Research Institute and former president of the American Society of Human Genetics.
- Heidi L. Rehm, PhD, FACMG, director of the Partners Healthcare Laboratory for Molecular Medicine, medical director of the Broad Institute's Clinical Research Sequencing Platform, and associate professor of pathology at Brigham and Women's Hospital and Harvard Medical School. Through her leadership roles in the NIH-funded Clinical Genome Resource program and the international Global Alliance for Genomics and Health as well as committee roles in the American College of Medical Genetics and Genomics, she has been instrumental in developing standards and resources to support data sharing, genomic sequencing and the interpretation of genetic variation.
- Amy Sturm, MS, CGC, professor and director of Cardiovascular Genomic Counseling at the Geisinger Health System Genomic Medicine Institute. She previously served on the National Society of Genetic Counselors (NSGC) Board of Directors and is currently the Cardiovascular Genetics Expert for NSGC's Expert Media Panel. Ms. Sturm's research interests include the development of novel, patient-centered, scalable genomic counseling models.
- Sharon F. Terry, MA, president and CEO of Genetic Alliance and cofounder of the Genetic Alliance Registry and Biobank. She is also the founding CEO of PXE International. She is co-PI of PCORnet's Coordinating Center and the co-chair of the National Academy of Medicine Genomics and Health Roundtable. She led the coalition instrumental in passing the Genetic Information Nondiscrimination Act. She is a citizen scientist and advocate.
- Eliezer Van Allen, MD, assistant professor of medicine at Harvard Medical School, clinician at Dana-Farber/Partners Cancer Care, and associate member at the Broad Institute of MIT and Harvard. He is a computational biologist and medical oncologist; his research focuses on computational cancer genomics and applying new technologies to precision cancer medicine.
- Catherine A. Wicklund, MS, CGC, director of the Graduate Program in Genetic Counseling at Northwestern University and associate professor in the Department of Obstetrics and Gynecology. She is past president of the National Society of Genetic Counselors (NSGC) and NSGCs' representative on the National Academies of Sciences, Engineering, Medicine Roundtable on Genomics and Precision Health. Ms. Wicklund's expertise is in genetic counseling and genomic education and her research interests include bringing personalized medicine into broader clinical use.
"Our vision is a world where genomic information is fully accessible and integrated into health and well-being," said Genome Medical co-founder and CEO Lisa Alderson. "Our scientific advisory board members share a commitment to providing physicians and patients with rapid access to trusted genetic advisors. Their insights will help us to build a world-class service delivering the benefits of genomic medicine to everyone."
Genome Medical has built a network of genetics experts who are now offering telemedicine consultations to early access customers in more than 40 states (soon to be all 50 states). Genome Medical offers telegenetics sessions for predisposition testing, reproductive health and cancer genetics. Cardiovascular genetics services are coming later this year, with pediatric genetics to follow.
About Genome Medical
We are a genomics precision medicine company with a network of genetics specialists helping patients and clinicians access and use genetic services to improve health, diagnose and prevent disease, and lower the cost of care. Our goal is to bridge the gap between genomic technology and medical practice by creating a scalable, efficient model for lifelong genome-centered health care. To learn more, please visit https://www.genomemedical.com/ or find us on Twitter @GenomeMed.